Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Finance > Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut

Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut

Published by Global Banking & Finance Review®

Posted on February 6, 2026

1 min read

Last updated: February 6, 2026

Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut - Finance news and analysis from Global Banking & Finance Review

Tags:valuations equity investment

Quick Summary

Agomab Therapeutics' shares fell 8% in their Nasdaq debut, valuing the company at $716 million. The Belgium-based biotech faced a negative initial market reaction.

Agomab Therapeutics Sees 8% Drop in Nasdaq Debut, Valued at $716 Million

Agomab Therapeutics Nasdaq Debut

Feb 6 (Reuters) - Shares of Agomab Therapeutics fell about 8% in their Nasdaq debut on Friday, valuing the Belgium-based company at $716.4 million.

Initial Market Reaction

(Reporting by Prakhar Srivastava in Bengaluru; Editing by Shailesh Kuber)

Key Takeaways

•Agomab Therapeutics shares fell 8% on Nasdaq debut.
•The company is valued at $716.4 million post-debut.
•Initial market reaction was negative.
•Agomab is a Belgium-based biotech firm.
•The debut was reported by Reuters.

Frequently Asked Questions about Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut

1What is a Nasdaq debut?

A Nasdaq debut refers to the first day a company's shares are traded on the Nasdaq stock exchange, marking its entry into the public market.

2What is market valuation?

Market valuation is the total value of a company's outstanding shares of stock, calculated by multiplying the share price by the total number of shares.

3What is an equity investment?

An equity investment involves purchasing shares of a company, giving the investor ownership rights and a claim on a portion of the company's assets and earnings.

Frequently Asked Questions

1What is a Nasdaq debut?

A Nasdaq debut refers to the first day a company's shares are traded on the Nasdaq stock exchange, marking its entry into the public market.

2What is market valuation?

Market valuation is the total value of a company's outstanding shares of stock, calculated by multiplying the share price by the total number of shares.

3What is an equity investment?

An equity investment involves purchasing shares of a company, giving the investor ownership rights and a claim on a portion of the company's assets and earnings.